So Now What? Implications of the Supreme Court’s Myriad Ruling

by Foley Hoag LLP
Contact

Late last week, the United States Supreme Court issued its long-awaited decision in Association of Molecular Pathology v. Myriad Genetics, Inc. The Court held unanimously that full-length wild-type DNA molecules are not patent-eligible under the Patent Act, even when isolated, but are instead “products of nature” that cannot be patented. Importantly, the Court also concluded that cDNAs – DNA molecules in which the naturally occurring non-coding regions (introns) are absent – are patent-eligible. The decision is likely to have wide-ranging impact on the biotechnology industry in litigation, patent prosecution, and licensing.

The challenged claims in Myriad were directed to naturally occurring genes that play a role in breast cancer. The Court held that an isolated, naturally occurring gene or gene fragment was not a new “composition of matter” under § 101 of the Patent Act, because such a gene had all the same genetic information the DNA would have in the body. The Court rejected arguments made by Myriad and adopted by the Federal Circuit that isolating a DNA molecule by cleaving the chemical bonds that join it to flanking DNA sequences is enough to render the molecule patent-eligible.

In contrast, the Court held that cDNAs were patent-eligible because they were “unquestionably … something new.” While the Court did not explain its rationale in detail, the justices appear to have reasoned that cDNAs are not naturally occurring and are synthesized from RNA in the laboratory. The Court’s reasoning almost certainly validates the patent-eligibility of highly engineered DNAs such as those coding for humanized or chimeric antibodies.

The Court briefly addressed claims drawn to naturally occurring DNA fragments, observing that “very short series of DNA may have no intervening introns to remove when creating cDNA. In that situation, a short strand of cDNA may be indistinguishable from natural DNA.” Under this reasoning, a short fragment would not be patent-eligible if it had a wild-type DNA sequence even if it was originally created as part of a cDNA.

At oral argument, the justices evidenced some uneasiness with the finer points of molecular biology underlying the patent issues. In a separate concurring opinion, Justice Scalia expressed his own concerns and refused to join in the Court’s scientific discussion, writing, “I am unable to affirm those [scientific] details on my own knowledge or even my own belief.”

Because of the highly technical subject matter, the Court appears to have kept its opinion deliberately narrow. Even so, some of the Court’s reasoning is less than clear. Most notably, the Court distinguished between “naturally occurring” and “synthetically created” DNAs, despite the fact that DNAs having a naturally occurring sequence can be readily synthesized in a laboratory. The Court specifically expressed no opinion as to the patent-eligibility of inventions directed to “DNA in which the order of the naturally occurring nucleotides has been altered.”

The Myriad ruling draws on the Court’s previous ruling in Mayo Collaborative Services v. Prometheus Laboratories, Inc., a case that addressed the patent-eligibility of method or process claims. The two cases together expand the Court’s previous holdings that “laws of nature” and “products of nature” are not patent-eligible and apply them to the life sciences.

The effects of the ruling going forward are, in a word, myriad.

For patent litigation:

While the opinion appears to hold that patent claims directed to isolated wild-type genes or gene fragments (and, by extension, other wild-type DNAs such as enhancers, promoters, etc.) are invalid, the decision presents an open field to litigate the validity of claims drawn to:

  • Purified, naturally occurring proteins synthesized in host-cell expression systems;
  • Non-mutant wild-type DNA sequences that have been trivially altered in non-natural ways, such as by ligation to a known sequence, or by labeling; and
  • DNAs that have been “synthetically created” but could theoretically be found in nature (such as certain types of mutant DNAs, which the Court expressly declined to consider).

More generally, the Court did not provide guidance about the extent to which a naturally occurring DNA sequence must be modified to become patent-eligible, nor did it suggest how it would rule on other purified, isolated, or synthesized materials that may have a naturally occurring counterpart. All of these issues are likely to be the subject of future patent litigation.

For patent prosecution:

It will be extremely important to draft claims that clearly differentiate between the claimed invention and any naturally occurring form of the DNA. For example, a human DNA sequence incorporated into a non-human mammalian chromosome may pass muster even if the isolated DNA itself would not (assuming that the DNA meets other requirements for patentability such as non-obviousness). Claims should be directed to plasmids, vectors, transformed host cells, or other constructs including the DNA sequence of interest to make clear that the claims do not encompass naturally occurring embodiments. Patent applicants should take advantage of the Court’s ruling that cDNAs are patent-eligible by claiming those, even in isolated form. Where an invention relies on the use of intronic sequences (the sequences omitted in a cDNA), it may be beneficial to disclose and claim non-natural introns such as chimeric introns. The written description should emphasize the differences between the natural composition of matter and the claimed invention. Patent applicants with vulnerable claims should add new method claims about how to create or use the DNAs of interest and should add construct claims, as discussed above. Finally, patentees who no longer have applications pending may seek to narrow and strengthen their claims by initiating reissue proceedings.

For patent licensing:

Licensors and licensees should review licensed patent portfolios to determine if any licensed patents contain only claims drawn to wild-type DNAs, because such patents may be invalid in their entirety. While the ruling may invalidate some claims of many patents, it is unlikely to invalidate all claims in a patent. Most patents have both broad DNA claims (which may now be invalid) and claims drawn to cell lines, vectors, and chimeric or non-natural mutant DNAs (which are probably still valid).


 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Foley Hoag LLP | Attorney Advertising

Written by:

Foley Hoag LLP
Contact
more
less

Foley Hoag LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.